1
|
Park SR, Lee JH, Kim K, Kim TM, Lee SH, Choo YK, Kim KS, Ko K. Expression and In Vitro Function of Anti-Breast Cancer Llama-Based Single Domain Antibody VHH Expressed in Tobacco Plants. Int J Mol Sci 2020; 21:E1354. [PMID: 32079309 PMCID: PMC7072948 DOI: 10.3390/ijms21041354] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/28/2020] [Accepted: 02/13/2020] [Indexed: 12/18/2022] Open
Abstract
Overexpression of human epidermal growth factor receptor type 2 (HER2) is considered as a prognostic factor of breast cancer, which is positively associated with recurrence when cancer metastasizes to the lymph nodes. Here, we expressed the single variable domain on a heavy chain (VHH) form of anti-HER2 camelid single domain antibody in tobacco plants and compared its in vitro anticancer activities with the anti-HER2 full size antibody. The gene expression cassette containing anti-HER2 camelid single domain antibody VHH fused to human IgG Fc region with KDEL endoplasmic reticulum (ER) (VHH-FcK) was transferred into the tobacco plant via the Agrobacterium-mediated transformation. The transformants were screened with polymerase chain reaction and Western blot analyses. Enzyme-linked immunosorbent assay (ELISA) confirmed the binding of the purified anti-HER2 VHH-FcK to the HER2-positive breast cancer cell line, SK-BR-3. Migration assay results confirmed anticancer activity of the plant-derived anticancer camelid single chain antibody. Taken together, we confirmed the possibility of using anti-HER2 VHH-FcK as a therapeutic anticancer agent, which can be expressed and assembled and purified from a plant expression system as an alternative antibody production system.
Collapse
Affiliation(s)
- Se Ra Park
- Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea; (S.R.P.); (J.-H.L.); (K.K.)
| | - Jeong-Hwan Lee
- Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea; (S.R.P.); (J.-H.L.); (K.K.)
| | - Kibum Kim
- Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea; (S.R.P.); (J.-H.L.); (K.K.)
- Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul 156-756, Korea
| | - Taek Min Kim
- Major of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon-National University, Incheon 22012, Korea; (T.M.K.); (S.H.L.)
| | - Seung Ho Lee
- Major of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon-National University, Incheon 22012, Korea; (T.M.K.); (S.H.L.)
| | - Young-Kug Choo
- Department of Biological science, College of Natural Sciences, Wonkwang University, 460, Iksan-daero, Iksan-si, Jeollabuk-do 54538, Korea;
| | - Kyung Soo Kim
- Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul 156-756, Korea
| | - Kisung Ko
- Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea; (S.R.P.); (J.-H.L.); (K.K.)
| |
Collapse
|